A Phase IIIb, Multinational, Multicenter, Open-Label Extension Study Assessing the Long-Term Safety of PRN Intravitreal Injections of DE-109 in Subjects With Non-Infectious Uveitis of the Posterior Segment of the Eye Who Have Participated in the SAKURA Development Program



Status:Completed
Conditions:Ocular
Therapuetic Areas:Ophthalmology
Healthy:No
Age Range:18 - Any
Updated:9/27/2018
Start Date:September 24, 2014
End Date:November 27, 2017

Use our guide to learn which trials are right for you!

The objective of this extension study is to evaluate the long-term safety of treatment with
DE-109 (440 μg) in subjects with non-infectious uveitis of the posterior segment of the eye
who have participated in the SAKURA development program.

This is a multicenter, open-label, extension study of intravitreal injections of the 440 μg
dose of DE-109 in subjects with non-infectious uveitis of the posterior segment who received
any dose of DE-109 and exited the SAKURA program under Santen Protocol 32-007, Amendment 05.

Subjects who were randomized and received at least two injections of DE-109 during the first
five months of the SAKURA program and obtained clinical benefit from the study medication, as
determined by the Investigator, may be considered for entry in this 12-month extension study.
The minimum time lag from last injection in the SAKURA program to entry into the current
protocol is 60 days.

Inclusion Criteria:

1. Participated in the SAKURA study

2. Received clinical benefit from treatment in the SAKURA study

3. Ability to sign informed consent and attend all study visits

Exclusion Criteria:

1. Uveitis of infectious etiology

2. Implanted device

3. Suspected or confirmed central nervous system or ocular lymphoma

4. Uncontrolled glaucoma

5. Significant ocular disease

6. Intravitreal injections in the past 60 days

7. Intraocular surgery or treatment

8. Ocular or periocular infection

9. History of herpetic infection

10. Toxoplasmosis or toxoplasmosis scar

11. Ocular malignancy

12. Vitrectomy

13. Allergy or hypersensitivity to study drug

14. Participation in other uveitis device clinical trials within 30 days

15. Any recent systemic condition/infection

16. Immunosuppressive therapy or immunocomprimised

17. Cytomegalovirus infection

18. Malignancy in remission

19. Females who are pregnant or lactating and who are not using adequate contraceptive

20. Medical marijuana or illegal drug use

21. Systemic saroidosis

22. Therapeutic radiation to the head or neck
We found this trial at
14
sites
?
mi
from
Phoenix, AZ
Click here to add this to my saved trials
?
mi
from
Austin, TX
Click here to add this to my saved trials
?
mi
from
Golden, CO
Click here to add this to my saved trials
?
mi
from
Graz,
Click here to add this to my saved trials
?
mi
from
Jackson, MI
Click here to add this to my saved trials
New Brunswick, New Jersey 08901
?
mi
from
New Brunswick, NJ
Click here to add this to my saved trials
?
mi
from
New York, NY
Click here to add this to my saved trials
?
mi
from
Oak Park, IL
Click here to add this to my saved trials
?
mi
from
Orchard Park, NY
Click here to add this to my saved trials
Palisades Park, New Jersey 07650
?
mi
from
Palisades Park, NJ
Click here to add this to my saved trials
?
mi
from
Sacramento, CA
Click here to add this to my saved trials
?
mi
from
Saint Louis, MO
Click here to add this to my saved trials
?
mi
from
Salt Lake City, UT
Click here to add this to my saved trials
?
mi
from
Tampa, FL
Click here to add this to my saved trials